Vanguard reports 0% stake in United Therapeutics

United Therapeutics Corp ownership update: The Vanguard Group filed Amendment No. 13 to report 0 shares beneficially owned, representing 0% of Common Stock as of 03/13/2026.

Accepted by SEC EDGAR 03/27/2026 - 01:53 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

United Therapeutics Corp ownership update: The Vanguard Group filed Amendment No. 13 to report 0 shares beneficially owned, representing 0% of Common Stock as of 03/13/2026. The filing explains an internal realignment on 01/12/2026 that led to disaggregated reporting by Vanguard subsidiaries.

Insights

Institutional Ownership Analyst

Vanguard reports no beneficial ownership after internal realignment.

The amendment shows The Vanguard Group holds 0 shares of United Therapeutics Common Stock and reports 0% ownership as of 03/13/2026. The filing cites a 01/12/2026 internal realignment and SEC Release No. 34-39538 as the basis for disaggregated reporting.

Cash‑flow treatment and any subsidiary holdings are not disclosed in the excerpt; subsequent filings by the named subsidiaries may list beneficial positions separately.

Regulatory Compliance Specialist

Amendment applies disaggregation guidance from SEC Release No. 34-39538.

The filing references SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately following an internal realignment on 01/12/2026. The statement formalizes reliance on that release for separate reporting.

Ownership percentages and voting/dispositive powers are reported as 0 in this amendment; any holdings by related entities will appear in their own filings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Does The Vanguard Group own United Therapeutics (UTHR) shares per this filing?

No, The Vanguard Group reports 0 shares and 0% ownership for United Therapeutics as of 03/13/2026. The amendment states Vanguard underwent an internal realignment on 01/12/2026, after which subsidiaries will report separately under SEC guidance.

Why does the Schedule 13G/A show zero ownership for Vanguard in UTHR?

The filing attributes the change to an internal realignment on 01/12/2026 and reliance on SEC Release No. 34-39538. Vanguard states certain subsidiaries will now report beneficial ownership separately from The Vanguard Group, leading to this amendment showing 0 shares.

Will related Vanguard entities report any United Therapeutics holdings separately?

Yes. The amendment states that subsidiaries or business divisions of The Vanguard Group will report beneficial ownership on a disaggregated basis under SEC Release No. 34-39538. Any such subsidiary filings would list their own share counts and percentages separately.

What voting and dispositive powers does Vanguard claim for UTHR here?

The filing reports 0 for sole and shared voting and dispositive powers and a 0% stake. Each listed power (sole vote, shared vote, sole dispositive, shared dispositive) is reported as 0 in the amendment dated 03/27/2026.

Who signed the Schedule 13G/A amendment for Vanguard and when?

The amendment is signed by Ashley Grim, Head of Global Fund Administration. The signature block shows the date 03/27/2026, confirming the filing's execution after the reported ownership date of 03/13/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 13)

United Therapeutics Corp

(Name of Issuer)

Common Stock

(Title of Class of Securities)

91307C102

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 91307C102

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: United Therapeutics Corp
(b)	Address of issuer's principal executive offices: 1040 Spring Street, Silver Spring, MD, 20910
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/27/2026